Originally published as JCO Early Release 10.1200/JCO.2007.14.2364 on October 22 2007

This Article Full Text Full Text (PDF) Journal of Oncology Practice Summary Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Harris, L. Articles by Bast, R. C. Search for Related Content PubMed PubMed Citation Articles by Harris, L. Articles by Bast, R. C., Jr Related Articles Related Correspondence Social Bookmarking                            What's this?

American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer

Lyndsay Harris, Herbert Fritsche, Robert Mennel, Larry Norton, Peter Ravdin, Sheila Taube, Mark R. Somerfield, Daniel F. Hayes, Robert C. Bast, Jr

From the Yale Cancer Center, Yale University, New Haven, CT; M.D. Anderson Cancer Center, Houston; Texas Oncology PA, Dallas, TX; Memorial Sloan-Kettering Cancer Center, New York, NY; National Cancer Institute, Bethesda, MD; American Society of Clinical Oncology, Alexandria, VA; University of Michigan Medical Center, Ann Arbor, MI

Address reprint requests to American Society of Clinical Oncology, 1900 Duke St, Suite 200, Alexandria, VA 22314; e-mail: guidelines{at}asco.org

Purpose To update the recommendations for the use of tumor marker tests in the prevention, screening, treatment, and surveillance of breast cancer.

Methods For the 2007 update, an Update Committee composed of members from the full Panel was formed to complete the review and analysis of data published since 1999. Computerized literature searches of MEDLINE and the Cochrane Collaboration Library were performed. The Update Committee's literature review focused attention on available systematic reviews and meta-analyses of published tumor marker studies. In general, significant health outcomes (overall survival, disease-free survival, quality of life, lesser toxicity, and cost-effectiveness) were used for making recommendations.

Recommendations and Conclusions Thirteen categories of breast tumor markers were considered, six of which were new for the guideline. The following categories showed evidence of clinical utility and were recommended for use in practice: CA 15-3, CA 27.29, carcinoembryonic antigen, estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2, urokinase plasminogen activator, plasminogen activator inhibitor 1, and certain multiparameter gene expression assays. Not all applications for these markers were supported, however. The following categories demonstrated insufficient evidence to support routine use in clinical practice: DNA/ploidy by flow cytometry, p53, cathepsin D, cyclin E, proteomics, certain multiparameter assays, detection of bone marrow micrometastases, and circulating tumor cells.

published online ahead of print at www.jco.org on October 22, 2007.

Approved by the Board of Directors Executive Committee on July 12, 2007.

Authors’ disclosures of potential conflicts of interest and author contributions are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

Related Correspondence

• Reaction to American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer
  Rene Bernards
  JCO 2008 26: 2057-2058 [Full Text]
• Inconsistent Criteria Used in American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer
  Fatima Cardoso, Mahasti Saghatchian, Alastair Thompson, Emiel Rutgers, and for the TRANSBIG Consortium Steering Committee
  JCO 2008 26: 2058-2059 [Full Text]

This article has been cited by other articles:

				R. S. Finn, R. Gagnon, A. Di Leo, M. F. Press, M. Arbushites, and M. Koehler Prognostic and Predictive Value of HER2 Extracellular Domain in Metastatic Breast Cancer Treated With Lapatinib and Paclitaxel in a Randomized Phase III Study J. Clin. Oncol., November 20, 2009; 27(33): 5552 - 5558. [Abstract] [Full Text] [PDF]

				R. M. Simon, S. Paik, and D. F. Hayes Use of Archived Specimens in Evaluation of Prognostic and Predictive Biomarkers J Natl Cancer Inst, November 4, 2009; 101(21): 1446 - 1452. [Abstract] [Full Text] [PDF]

				A H Sims Bioinformatics and breast cancer: what can high-throughput genomic approaches actually tell us? J. Clin. Pathol., October 1, 2009; 62(10): 879 - 885. [Abstract] [Full Text] [PDF]

				F. Cardoso, P. L. Bedard, E. P. Winer, O. Pagani, E. Senkus-Konefka, L. J. Fallowfield, S. Kyriakides, A. Costa, T. Cufer, K. S. Albain, et al. International Guidelines for Management of Metastatic Breast Cancer: Combination vs Sequential Single-Agent Chemotherapy J Natl Cancer Inst, September 2, 2009; 101(17): 1174 - 1181. [Abstract] [Full Text] [PDF]

				M. Cianfrocca and W. Gradishar New Molecular Classifications of Breast Cancer CA Cancer J Clin, September 1, 2009; 59(5): 303 - 313. [Abstract] [Full Text] [PDF]

				C. Ahlin, W. Zhou, M. Holmqvist, L. Holmberg, C. Nilsson, K. Jirstrom, C. Blomqvist, R.-M. Amini, and M.-L. Fjallskog Cyclin A Is a Proliferative Marker with Good Prognostic Value in Node-Negative Breast Cancer Cancer Epidemiol. Biomarkers Prev., September 1, 2009; 18(9): 2501 - 2506. [Abstract] [Full Text] [PDF]

				J.-C. Yu, S.-l. Ding, C.-H. Chang, S.-H. Kuo, S.-T. Chen, G.-C. Hsu, H.-M. Hsu, M.-F. Hou, L. Y. Jung, C.-W. Cheng, et al. Genetic susceptibility to the development and progression of breast cancer associated with polymorphism of cell cycle and ubiquitin ligase genes Carcinogenesis, September 1, 2009; 30(9): 1562 - 1570. [Abstract] [Full Text] [PDF]

				K. Bohmann, G. Hennig, U. Rogel, C. Poremba, B. M. Mueller, P. Fritz, S. Stoerkel, and K.-L. Schaefer RNA Extraction from Archival Formalin-Fixed Paraffin-Embedded Tissue: A Comparison of Manual, Semiautomated, and Fully Automated Purification Methods Clin. Chem., September 1, 2009; 55(9): 1719 - 1727. [Abstract] [Full Text] [PDF]

				J.-Y. Choi, W. E. Barlow, K. S. Albain, C.-C. Hong, J. G. Blanco, R. B. Livingston, W. Davis, J. M. Rae, I-T. Yeh, L. F. Hutchins, et al. Nitric Oxide Synthase Variants and Disease-Free Survival among Treated and Untreated Breast Cancer Patients in a Southwest Oncology Group Clinical Trial Clin. Cancer Res., August 15, 2009; 15(16): 5258 - 5266. [Abstract] [Full Text] [PDF]

				J. S. Ross and E. A. Slodkowska Circulating and Disseminated Tumor Cells in the Management of Breast Cancer Am J Clin Pathol, August 1, 2009; 132(2): 237 - 245. [Abstract] [Full Text] [PDF]

				F. Correa Geyer and J. S. Reis-Filho Microarray-based Gene Expression Profiling as a Clinical Tool for Breast Cancer Management: Are We There Yet? International Journal of Surgical Pathology, August 1, 2009; 17(4): 285 - 302. [Abstract] [PDF]

				C. Thomssen, N. Harbeck, J. Dittmer, S. R. Abraha-Spaeth, N. Papendick, A. Paradiso, B. Lisboa, F. Jaenicke, M. Schmitt, and M. Vetter Feasibility of Measuring the Prognostic Factors uPA and PAI-1 in Core Needle Biopsy Breast Cancer Specimens J Natl Cancer Inst, July 15, 2009; 101(14): 1028 - 1029. [Full Text] [PDF]

				R. Franceschini, C. Trevisiol, R. Dittadi, and M. Gion Tumour markers requesting pattern with regards to different organizational settings in Italy: a survey of hospital laboratories Ann Clin Biochem, July 1, 2009; 46(4): 316 - 321. [Abstract] [Full Text] [PDF]

				V. Guarneri and P. Conte Metastatic Breast Cancer: Therapeutic Options According to Molecular Subtypes and Prior Adjuvant Therapy Oncologist, July 1, 2009; 14(7): 645 - 656. [Abstract] [Full Text] [PDF]

				E E Torlakovic, K Naresh, M Kremer, J van der Walt, E Hyjek, and A Porwit Call for a European programme in external quality assurance for bone marrow immunohistochemistry; report of a European Bone Marrow Working Group pilot study J. Clin. Pathol., June 1, 2009; 62(6): 547 - 551. [Abstract] [Full Text] [PDF]

				J. K. Yi, J. W. Chang, W. Han, J. W. Lee, E. Ko, D. H. Kim, J.-Y. Bae, J. Yu, C. Lee, M.-H. Yu, et al. Autoantibody to Tumor Antigen, Alpha 2-HS Glycoprotein: A Novel Biomarker of Breast Cancer Screening and Diagnosis Cancer Epidemiol. Biomarkers Prev., May 1, 2009; 18(5): 1357 - 1364. [Abstract] [Full Text] [PDF]

				J. H. Lee, E. L. Rosen, and D. A. Mankoff The Role of Radiotracer Imaging in the Diagnosis and Management of Patients with Breast Cancer: Part 2--Response to Therapy, Other Indications, and Future Directions J. Nucl. Med., May 1, 2009; 50(5): 738 - 748. [Abstract] [Full Text] [PDF]

				S. Chourin, D. Georgescu, C. Gray, C. Guillemet, A. Loeb, C. Veyret, and J.-P. Basuyau Value of CA 15-3 determination in the initial management of breast cancer patients Ann. Onc., May 1, 2009; 20(5): 962 - 964. [Full Text] [PDF]

				M. P.S. Dunphy and J. S. Lewis Radiopharmaceuticals in Preclinical and Clinical Development for Monitoring of Therapy with PET J. Nucl. Med., May 1, 2009; 50(Suppl_1): 106S - 121S. [Abstract] [Full Text] [PDF]

				D. F. Hayes Clinical Utility of Tumor Markers: Study Design and Evaluation Am. Assoc. Cancer Res. Educ. Book, April 18, 2009; 2009(1): 273 - 277. [Full Text] [PDF]

				A. F. Leary, W. M. Hanna, M. J. van de Vijver, F. Penault-Llorca, J. Ruschoff, R. Y. Osamura, M. Bilous, and M. Dowsett Value and Limitations of Measuring HER-2 Extracellular Domain in the Serum of Breast Cancer Patients J. Clin. Oncol., April 1, 2009; 27(10): 1694 - 1705. [Abstract] [Full Text] [PDF]

				A. A. Iverson, C. Gillett, P. Cane, C. D. Santini, T. M. Vess, L. Kam-Morgan, A. Wang, M. Eisenberg, C. M. Rowland, J. J. Hessling, et al. A Single-Tube Quantitative Assay for mRNA Levels of Hormonal and Growth Factor Receptors in Breast Cancer Specimens J. Mol. Diagn., March 1, 2009; 11(2): 117 - 130. [Abstract] [Full Text] [PDF]

				C. Sotiriou and L. Pusztai Gene-Expression Signatures in Breast Cancer N. Engl. J. Med., February 19, 2009; 360(8): 790 - 800. [Full Text] [PDF]

				D. Kanojia, M. Garg, S. Gupta, A. Gupta, and A. Suri Sperm-Associated Antigen 9, a Novel Biomarker for Early Detection of Breast Cancer Cancer Epidemiol. Biomarkers Prev., February 1, 2009; 18(2): 630 - 639. [Abstract] [Full Text] [PDF]

				M. Schmidt, A. Victor, D. Bratzel, D. Boehm, C. Cotarelo, A. Lebrecht, W. Siggelkow, J. G. Hengstler, A. Elsasser, M. Gehrmann, et al. Long-term outcome prediction by clinicopathological risk classification algorithms in node-negative breast cancer--comparison between Adjuvant!, St Gallen, and a novel risk algorithm used in the prospective randomized Node-Negative-Breast Cancer-3 (NNBC-3) trial Ann. Onc., February 1, 2009; 20(2): 258 - 264. [Abstract] [Full Text] [PDF]

				P. M. LoRusso, H. A. Burris III, S. F. Jones, R. A. Fleming, and K. M. Koch In Reply J. Clin. Oncol., January 10, 2009; 27(2): 316 - 317. [Full Text] [PDF]

				R. S. Huang and M. J. Ratain Pharmacogenetics and pharmacogenomics of anticancer agents CA Cancer J Clin, January 1, 2009; 59(1): 42 - 55. [Abstract] [Full Text] [PDF]

				M. Dowsett and A. K. Dunbier Emerging Biomarkers and New Understanding of Traditional Markers in Personalized Therapy for Breast Cancer Clin. Cancer Res., December 15, 2008; 14(24): 8019 - 8026. [Abstract] [Full Text] [PDF]

				C. M. Sturgeon, M. J. Duffy, U.-H. Stenman, H. Lilja, N. Brunner, D. W. Chan, R. Babaian, R. C. Bast Jr., B. Dowell, F. J. Esteva, et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast, and Ovarian Cancers Clin. Chem., December 1, 2008; 54(12): e11 - e79. [Abstract] [Full Text] [PDF]

				J.-Y. Pierga, F.-C. Bidard, C. Mathiot, E. Brain, S. Delaloge, S. Giachetti, P. de Cremoux, R. Salmon, A. Vincent-Salomon, and M. Marty Circulating Tumor Cell Detection Predicts Early Metastatic Relapse After Neoadjuvant Chemotherapy in Large Operable and Locally Advanced Breast Cancer in a Phase II Randomized Trial Clin. Cancer Res., November 1, 2008; 14(21): 7004 - 7010. [Abstract] [Full Text] [PDF]

				M. J. Duffy and J. Crown A Personalized Approach to Cancer Treatment: How Biomarkers Can Help Clin. Chem., November 1, 2008; 54(11): 1770 - 1779. [Abstract] [Full Text] [PDF]

				R. Simon The Use of Genomics in Clinical Trial Design Clin. Cancer Res., October 1, 2008; 14(19): 5984 - 5993. [Abstract] [Full Text] [PDF]

				D. P. Turner, V. J. Findlay, A. D. Kirven, O. Moussa, and D. K. Watson Global Gene Expression Analysis Identifies PDEF Transcriptional Networks Regulating Cell Migration during Cancer Progression Mol. Biol. Cell, September 1, 2008; 19(9): 3745 - 3757. [Abstract] [Full Text] [PDF]

				M. Cristofanilli, J. Reuben, and J. Uhr Circulating Tumor Cells in Breast Cancer: Fiction or Reality? J. Clin. Oncol., July 20, 2008; 26(21): 3656 - 3657. [Full Text] [PDF]

				D. F. Hayes and J. Smerage Is There a Role for Circulating Tumor Cells in the Management of Breast Cancer? Clin. Cancer Res., June 15, 2008; 14(12): 3646 - 3650. [Abstract] [Full Text] [PDF]

				D. F. Hayes, V. Stearns, J. Rae, D. Flockhart, and on behalf of the Consortium on Breast Cancer Pharm A Model Citizen? Is Tamoxifen More Effective Than Aromatase Inhibitors if We Pick the Right Patients? J Natl Cancer Inst, May 7, 2008; 100(9): 610 - 613. [Full Text] [PDF]

				A Vincent-Salomon, F C Bidard, and J Y Pierga Bone marrow micrometastasis in breast cancer: review of detection methods, prognostic impact and biological issues J. Clin. Pathol., May 1, 2008; 61(5): 570 - 576. [Abstract] [Full Text] [PDF]

				J. S. Ross, C. Hatzis, W. F. Symmans, L. Pusztai, and G. N. Hortobagyi Commercialized Multigene Predictors of Clinical Outcome for Breast Cancer Oncologist, May 1, 2008; 13(5): 477 - 493. [Abstract] [Full Text] [PDF]

				R. Bernards Reaction to American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer J. Clin. Oncol., April 20, 2008; 26(12): 2057 - 2058. [Full Text] [PDF]

				F. Cardoso, M. Saghatchian, A. Thompson, E. Rutgers, and for the TRANSBIG Consortium Steering Committee Inconsistent Criteria Used in American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer J. Clin. Oncol., April 20, 2008; 26(12): 2058 - 2059. [Full Text] [PDF]

				S. Bahri, J.-H. Chen, H. J. Yu, A. Kuzucan, O. Nalcioglu, and M.-Y. Su Can dynamic contrast-enhanced MRI (DCE-MRI) predict tumor recurrence and lymph node status in patients with breast cancer? Ann. Onc., April 1, 2008; 19(4): 822 - 824. [Full Text] [PDF]

				L. Pusztai Current Status of Prognostic Profiling in Breast Cancer Oncologist, April 1, 2008; 13(4): 350 - 360. [Abstract] [Full Text] [PDF]

				D. F. Hayes Markers for Predicting and Evaluating Response to Therapy for Breast Cancer ASCO Educational Book, January 1, 2008; 2008(1): 30 - 34. [Abstract] [Full Text] [PDF]